B.F. Ascher Halts Supplement/OTC Combo Sales Following FDA Warnings
This article was originally published in The Tan Sheet
Executive Summary
B.F. Ascher has discontinued the sale of its Melagesic PM dietary supplement/OTC combination in response to FDA's decision the product is an unapproved new drug, according to the agency
You may also be interested in...
FDA Warning Letter Review Suggests Aggressive Action Needed, Troy Says
The FDA Office of Chief Counsel's review of warning and untitled letters suggests the agency should be taking more aggressive enforcement actions, Chief Counsel Daniel Troy suggested Feb. 21
FDA Warning Letter Review Suggests Aggressive Action Needed, Troy Says
The FDA Office of Chief Counsel's review of warning and untitled letters suggests the agency should be taking more aggressive enforcement actions, Chief Counsel Daniel Troy suggested Feb. 21
FDA Warning Letter Review Suggests Aggressive Action Needed, Troy Says
The FDA Office of Chief Counsel's review of warning and untitled letters suggests the agency should be taking more aggressive enforcement actions, Chief Counsel Daniel Troy suggested Feb. 21